Maria Fleseriu Selected Research

Osilodrostat

1/2022	Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Authors' reply.
1/2021	Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
1/2020	Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
4/2016	Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
4/2014	LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Fleseriu Research Topics

Disease

43	Acromegaly 06/2022 - 10/2010
35	Neoplasms (Cancer) 03/2022 - 08/2006
33	Pituitary ACTH Hypersecretion 01/2022 - 01/2007
30	Cushing Syndrome 03/2022 - 01/2009
17	Pituitary Neoplasms (Pituitary Adenoma) 01/2020 - 01/2007
14	Adenoma (Adenomas) 11/2022 - 12/2012
14	Adrenal Insufficiency (Adrenal Gland Hypofunction) 03/2022 - 09/2009
11	Hyperglycemia 12/2020 - 09/2012
9	Prolactinoma (Prolactinomas) 01/2021 - 08/2006
7	ACTH-Secreting Pituitary Adenoma 02/2018 - 03/2011
6	Hypopituitarism (Sheehan's Syndrome) 01/2022 - 01/2010
4	Hyperprolactinemia 01/2020 - 02/2014
3	Hypophysitis 01/2022 - 10/2019
3	Nausea 01/2021 - 06/2012
3	Rare Diseases (Rare Disease) 01/2020 - 12/2016
3	Diabetes Mellitus 01/2019 - 11/2006
2	Infections 03/2022 - 01/2022
2	Pituitary Diseases (Disease, Anterior Pituitary) 01/2022 - 01/2020
2	Vomiting 01/2021 - 06/2012
2	Fatigue 03/2020 - 06/2012
2	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2020 - 10/2018
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2019 - 04/2018
2	Melanoma (Melanoma, Malignant) 10/2019 - 01/2010
2	Weight Gain 09/2019 - 12/2015
2	Osteoporosis 01/2018 - 05/2015
2	Critical Illness (Critically Ill) 06/2017 - 10/2009
2	Septic Shock (Toxic Shock Syndrome) 06/2017 - 09/2009
1	Thromboembolism 03/2022
1	Prediabetic State (Prediabetes) 03/2022
1	Inflammation (Inflammations) 01/2022
1	Cysts 01/2022
1	Pneumonia (Pneumonitis) 04/2021
1	COVID-19 01/2021
1	Injection Site Reaction 01/2021
1	Carcinoma (Carcinomatosis) 01/2021
1	Bradycardia 01/2021
1	Insulin Resistance 01/2021
1	Urinary Tract Infections (Urinary Tract Infection) 01/2021
1	Exanthema (Rash) 01/2021
1	Hypertension (High Blood Pressure) 12/2020
1	Dyslipidemias (Dyslipidemia) 12/2020
1	Drug-Related Side Effects and Adverse Reactions 08/2020
1	Infertility (Sterility) 03/2020
1	Cognitive Dysfunction 03/2020
1	Erectile Dysfunction 03/2020
1	Obesity 03/2020

Drug/Important Bio-Agent (IBA)

25	Hydrocortisone (Cortisol)FDA LinkGeneric 03/2022 - 09/2009
23	Growth Hormone (Somatotropin)IBA 03/2022 - 10/2010
20	Adrenocorticotropic Hormone (ACTH)FDA Link 03/2022 - 01/2007
20	pasireotideIBA 03/2022 - 01/2013
14	Somatostatin Receptors (Somatostatin Receptor)IBA 03/2022 - 06/2011
12	LigandsIBA 01/2022 - 06/2011
12	Octreotide (Sandostatin)FDA LinkGeneric 01/2022 - 11/2006
12	ProlactinIBA 12/2020 - 08/2006
11	Insulin-Like Growth Factor I (IGF-1)IBA 06/2022 - 06/2011
11	GlucocorticoidsIBA 03/2022 - 09/2009
10	Pharmaceutical PreparationsIBA 01/2022 - 09/2012
9	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2021 - 06/2012
9	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 08/2020 - 08/2013
8	pegvisomant FDA LinkGeneric 06/2022 - 08/2013
7	Insulin-Like PeptidesIBA 03/2022 - 12/2012
7	lanreotide (Somatuline)FDA Link 01/2022 - 06/2011
7	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 11/2006
7	Dopamine Agonists (Dopamine Agonist)IBA 01/2021 - 08/2013
7	Mifepristone (RU 486)FDA Link 09/2019 - 06/2012
5	OsilodrostatIBA 01/2022 - 04/2014
5	Insulin (Novolin)FDA Link 01/2020 - 06/2011
5	Biomarkers (Surrogate Marker)IBA 11/2016 - 11/2012
4	Cabergoline FDA LinkGeneric 08/2014 - 08/2006
3	Hormones (Hormone)IBA 11/2022 - 06/2017
3	Testosterone (Sustanon)FDA Link 03/2020 - 04/2016
2	Thyroid HormonesIBA 03/2020 - 09/2019
2	GadoliniumIBA 02/2020 - 02/2019
2	amsonic acid (DAS)IBA 01/2020 - 01/2019
2	Immune Checkpoint InhibitorsIBA 01/2020 - 10/2019
2	IpilimumabIBA 10/2019 - 01/2010
2	Corticotropin-Releasing HormoneIBA 06/2017 - 12/2016
2	Temozolomide (Temodar)FDA LinkGeneric 02/2017 - 03/2011
1	aryl hydrocarbon receptor-interacting proteinIBA 03/2022
1	Antihypertensive Agents (Antihypertensives)IBA 03/2022
1	Somatotropin Receptors (Growth Hormone Receptor)IBA 03/2022
1	ElectrolytesIBA 03/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2022
1	VaccinesIBA 01/2022
1	Protein Isoforms (Isoforms)IBA 02/2021
1	Growth Factor ReceptorsIBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Lapatinib (GW572016)FDA Link 01/2021
1	Aligeron (AS 2)IBA 01/2021

Therapy/Procedure

57	Therapeutics 11/2022 - 11/2006
12	Radiotherapy 12/2021 - 10/2010
6	Injections 01/2022 - 08/2014
4	Drug Therapy (Chemotherapy) 12/2019 - 08/2013
3	Adrenalectomy 01/2020 - 01/2007
2	Immunotherapy 01/2022 - 01/2020
2	Subcutaneous Injections 01/2021 - 12/2019
2	Bariatric Surgery 12/2015 - 01/2009
2	Investigational Therapies (Experimental Therapy) 08/2013 - 01/2010
1	Continuity of Patient Care 01/2021
1	Personal Protective Equipment 01/2021